One often reads a lot about positive study results on certain active ingredients. However, one often hears little later about failed MS active ingredients. Prof. Mathias Mäurer reports in this AMSEL video why this is the case and where one can read details about individual non-approved active ingredients.
Please consider using the automated translation of YouTube. You can activate this function by clicking on the settings symbol and choosing subtitles.
Speaking of failed MS active ingredients is actually wrong. It would be better to say: Active ingredients with negative study results. Unfortunately, it is in the nature of things that not all active ingredients that have been tested in the mouse model or for other diseases also work for human MS. That’s why they are tested little by little.
And there are countless reasons why an individual active ingredient does not pass the approval hurdle, possibly failing already after phase 1. Too little effect, too strong side effects, wrong study design… And – in rare cases – also differing views of international authorities.
An important factor in multiple sclerosis: That scientists worldwide are now researching more about neuroprotection and remyelination in MS. While the inflammatory level of MS can already be relatively well influenced by medication, the task of stopping the degeneration, possibly reversing existing damage, is much more complicated. Therefore, active ingredients with this approach often fail. Especially since the question of success measurement is not as simple as with the relapse rate.
Prof. Mathias Mäurer speaks in this video about what often falls by the wayside, namely active ingredients with negative study results such as green tea extract, high-dose biotin or Anti-Lingo1 (Opicinumab). And he reveals where you can look if you are interested in more details, such as the overview article „Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020“ on PubMed.
